1225452-44-7

Basic information

• Product Name: 4-(4-bromophenyl)-1-methylpiperidine-4-carbonitrile
• Synonyms: 4-(4-bromophenyl)-1-methylpiperidine-4-carbonitrile
• CAS NO: 1225452-44-7
• Molecular Weight: 279.18
• Mol File: 1225452-44-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(4-bromophenyl)-1-methylpiperidine-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-bromophenyl)-1-methylpiperidine-4-carbonitrile(1225452-44-7)
• EPA Substance Registry System: 4-(4-bromophenyl)-1-methylpiperidine-4-carbonitrile(1225452-44-7)

Safety Data

• Hazardous Substances Data: 1225452-44-7(Hazardous Substances Data)

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 55-86-7 mechlorethamine hydrochloride 

Downstream Products

• 1243268-86-1 4-[4-(benzhydrylidene-amino)-phenyl]-1-methyl-piperidine-4-carbonitrile 

Relevant articles and documents

PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS

The invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is -NR7(CO)R11; R2 is aryl, heteroaryl, fused aryl-C3-6-heterocycloalkyl or fused heteroaryl-C3-6- heterocycloalkyl, each of which is optionally substituted; each R7 is selected from hydrogen, C1-6-alkyl and C3-7-cycloalkyl, wherein said C1-6-alkyl is optionally substituted by one or more halogens; each R11 is independently selected from C1-6-alkyl, C3-7-cycloalkyl, C1-6alkyl-C3-7-cycloalkyl, C^-heterocycloalkyl, aryl and heteroaryl, each of which may be optionally substituted. Further aspects of the invention relate to pharmaceutical compositions comprising the same, and methods for treating or preventing a disorder selected from cancer, septic shock, Primary open Angle Glaucoma (POAG), hyperplasia, rheumatoid arthritis, psoriasis, artherosclerosis, retinopathy, osteoarthritis, endometriosis, chronic inflammation and Alzheimer's disease. Another aspect of the invention relates to the use of a compound as described above in the preparation of a medicament for the prevention or treatment of a disorder caused by, associated with or accompanied by any abnormal kinase activity, wherein the kinase is selected from TBK1, ERK8, CDK2, MARK3, YES1, VEG-FR, IKKepsilon and combinations thereof.